Yr20 Supplement Request Abstract CTN-0109 Randomized, placebo-controlled trial of extended-release naltrexone and monthly extended- release buprenorphine for cocaine use disorder (CURB-2) This is an 8-week, double-blind, randomized placebo-controlled trial to determine the efficacy of a combination of extended-release naltrexone (XR-NTX) and extended-release buprenorphine (XR-BUP) compared to placebo injections (PBO-Inje) for the treatment of cocaine use disorder (CUD). The primary objective is to evaluate whether assignment of 8 weeks of outpatient XR-NTX + XR-BUP compared to PBO-Inje reduces urine-verified cocaine use in study Weeks 5 through 8. The primary outcome measure is the proportion of cocaine-negative urine drug screens (UDS) obtained during Weeks 5 through 8 as measured for the XR-NTX + XR-BUP and PBO-Inj conditions. The secondary objective is to evaluate the effect of assignment to 8 weeks of XR-NTX + XR-BUP compared to PBO-Inj on self-report days of cocaine use, cocaine craving, safety, and treatment effectiveness. The secondary outcome measures are 1) Self-reported days of cocaine use and cocaine craving effects (Visual Analog Scale (VAS)) during Weeks 0-8; 2) Measures of adverse events during Weeks 0-8: number and severity of adverse events; number and outcomes (fatal/non-fatal) of overdose events reported; 3) Measures of Treatment Effectiveness Assessment (TEA) at Week 8. Yr20 Supplement Request Abstract CTN-0132 Randomized, Double-Blind, Active Placebo-Controlled Trial of Ketamine for Methamphetamine Use Disorder (KMD) This is a 12-week randomized, double-blind, controlled trial comparing intravenous (IV) ketamine against IV midazolam delivered over six weeks (acute phase of twice-weekly infusions during Weeks 1, 2, and 3, and one infusion during Week 4, followed by continuation-phase of one infusion during Week 6; total of eight (8) infusions over the six-week period) in 120 adults (30 per site) with moderate to severe methamphetamine use disorder (MUD) (without co-existing opioid use disorder [OUD] of moderate to severe severity).